Место тофацитиниба в лечении воспалительных заболеваний кишечника
________________________________________________
Nasonov E.L., Abdulganieva D.I., Fairushina I.F. The use of Tofacitinib in the treatment of inflammatory bowel disease. Therapeutic Archive. 2019; 91 (2): 8–108. DOI: 10.26442/00403660.2019.02.000155
Материалы доступны только для специалистов сферы здравоохранения. Авторизуйтесь или зарегистрируйтесь.
Ключевые слова: воспалительные заболевания кишечника, язвенный колит, болезнь Крона, ингибиторы JAK, тофацитиниб.
________________________________________________
Major advances in pharmacology of the 21st century include the development of a new class of drugs, which are low-molecular, chemically synthesized molecules (the so-called "small molecules"), the point of application of which is Janus kinase (Janus kinase, JAK) involved in intracellular cytokine signaling. The review examines the molecular aspects of the JAK-STAT signaling pathway, justifying the use of the JAK-kinase inhibitor (tofacitinib) in the treatment of inflammatory bowel disease.
Keywords: inflammatory bowel disease, ulcerative colitis, Crohn's disease, JAK inhibitors, tofacitinib.
2. Baumgart DC, Sandborn WJ. Crohn's disease. Lancet. 2012;380(9853):1590-605. doi: 10.1016/S0140-6736(12)60026-9
3. Park JH, Peyrin-Biroulet L, Eisenhut M, Shin JI. IBD immunopathogenesis: A comprehensive review of inflammatory molecules. Autoimmun Rev. 2017 Apr;16(4):416-26. doi: 10.1016/j.autrev.2017.02.013
4. De Souza HS, Fiocchi C. Immunopathogenesis of IBD: current state of the art. Nat Rev Gastroenterol Hepatol. 2016;13:13-27.
5. Ahluwalia B, Moraes L, Magnusson MK, Öhman L. Immunopathogenesis of inflammatory bowel disease and mechanisms of biological therapies. Scand J Gastroenterol. 2018;53(4):379-89. doi: 10.1080/00365521.2018.1447597
6. Neurath MF. Cytokines in inflammatory bowel disease. Nat Rev Immunol. 2014;14(5):329-42.
7. Chen ML, Sundrud MS. Cytokine networks and T-cell subsets in inflammatory bowel diseases. Inflam Bow Dis. 2016;22(5):1157-67. doi: 10.1097/MIB.0000000000000714
8. Rogler G. Resolution of inflammation in inflammatory bowel disease. Lancet Gastroenterol Hepatol. 2017;2(7):521-30. doi: 10.1016/S2468-1253(17)30031-6
9. Neurath M. Current and emerging therapeutic targets for IBD. Nat Rev Gastroenterol Hepatol. 2017;14(11):688. doi: 10.1038/nrgastro.2017.138
10. Kalliolias GD, Ivashkiv LB. TNF biology, pathogenetic mechanisms and emerging therapeutic strategies. Nat Rev Rheumatol. 2016;12:49-62.
11. Levin AD, Wildenberg ME, van den Brink GR. Mechanism of Action of Anti-TNF Therapy in Inflammatory Bowel Disease. J Crohns Colitis. 2016 Aug;10(8):989-97. doi: 10.1093/ecco-jcc/jjw053. Epub 2016 Feb 19.
12. Berns M, Hommes DW. Anti-TNF-alpha therapies for the treatment of Crohn’s disease: the past, present and future. Expert Opin Investigat Drug. 2016;25(2):129-43. doi: 10.1517/13543784.2016.1126247
13. Dart RJ, Samaan MA, Powell N, Irving PM. Vedolizumab: toward a personalized therapy paradigm for people with ulcerative colitis. Clin Exp Gastroenterol. 2017;10:57-66.
14. Amiot A, Grimaud JC, Peyrin-Biroulet L, et al. Effectiveness and safety of vedolizumab induction therapy for patients with inflammatory bowel disease. Clin Gastroenterol Hepatol. 2016;14(11):1593-601. doi: 10.1016/j.cgh.2016.02.016. e2
15. Vermeire S, Gils A, Accossato P, Lula S, Marren A. Immunogenicity of biologics in inflammatory bowel disease. Ther Adv Gastroenterol. 2018 Jan 21;11:1756283X17750355. doi: 10.1177/1756283X177
16. Schwartz DM, Kanno Y, Villarino A, Ward M, Gadina M, O’Shea JJ. JAK inhibition as a therapeutic strategy for immune and inflammatory diseases. Nat Rev Drug Discov. 2017 Dec;16(12):843-62. doi: 10.1038/nrd.2017.201. Epub 2017 Nov 6.
17. Winthrop KL. The emerging safety profile of JAK inhibitors in rheumatic disease. Nat Rev Rheumatol. 2017 Apr;13(4):234-43. doi: 10.1038/nrrheum.2017.23
18. Banerjee S, Biehl A, Gadina M, Hasni S, Schwartz DM. JAK-STAT Signaling as a Target for Inflammatory and Autoimmune Diseases: Current and Future Prospects. Drugs. 2017 Apr;77(5):521-46. doi: 10.1007/s40265-017-0701-9
19. Насонов Е.Л. Новые подходы к фармакотерапии ревматоидного артрита: тофацитиниб. Научно-практическая ревматология. 2014;52(2):209-21 [Nasonov EL. New approaches to pharmacotherapy of rheumatoid arthritis: tofacitinib. Nauchno-Prakticheskaya Revmatologiya = Rheumatology Science and Practice. 2014;52(2):209-21 (In Russ.)]. doi: 10.14412/1995-4484-2014-209-221
20. Baker KF, Isaacs JD. Novel therapies for immune-mediated inflammatory diseases: What can we learn from their use in rheumatoid arthritis, spondyloarthritis, systemic lupus erythematosus, psoriasis, Crohn's disease and ulcerative colitis? Ann Rheum Dis. 2018 Feb;77(2):175-87. doi: 10.1136/annrheumdis-2017-211555
21. Panés J, Sandborn WJ, Schreiber S, Sands BE, Vermeire S, et al. Tofacitinib for induction and maintenance therapy of Crohn’s disease: results of two phase IIb randomised placebo-controlled trials. Gut. 2017;66(6):1049-59. doi: 10.1136/gutjnl-2016-312735
22. Boland BS, Vermeire S. Janus Kinase Antagonists and Other Novel Small Molecules for the Treatment of Crohn’s Disease. Gastroenterol Clin North Am. 2017 Sep;46(3):627-44. doi: 10.1016/j.gtc.2017.05.015
23. Soendergaard C, Bergenheim FH, Bjerrum JT, Nielsen OH. Targeting JAK-STAT signal transduction in IBD. Pharmacol Ther. 2018 Jul 23. pii: S0163-7258(18)30122-0. doi: 10.1016/j.pharmthera.2018.07.003
24. Olivera P, Danese S, Peyrin-Biroulet L. JAK inhibition in inflammatory bowel disease. Expert Rev Clin Immunol. 2017 Jul;13(7):693-703. doi: 10.1080/1744666X.2017.1291342
25. Шапина М.В., Халиф И.Л. Эффективность и безопасность тофацитиниба при язвенном колите (обзор литературы). Колопроктология. 2018;65(3):94-102 [Shapina MV, Khalif IL. Efficacy and safety of tofacitinib in ulcerative colitis (literature review). Koloproktologiya. 2018;65(3):94-102 (In Russ.)].
26. Hammarén HM, Virtanen AT, Raivola J, Silvennoinen O. The regulation of JAKs in cytokine signaling and its breakdown in disease. Cytokine. 2018 Apr 20. pii: S1043-4666(18)30127-3. doi: 10.1016/j.cyto.2018.03.041
27. Changelian PS, Flanaan ME, Ball DJ, et al. Prevention оf organ allograft rejection by a specific Janus kinase 3 inhibitor. Science. 2003;302:875-8.
28. Flanagan ME, Blumenkopf TA, Brisette WH, et al. Discovery of CP-690550: a potent and selective Janus kinase (JAK) inhibitor for the treatment of autoimmune diseases and organ transplantant rejection. J Med Chem. 2010;53:8468-84.
29. Karaman MW, Herrgard S, Treiber DK, et al. A quantitative analysis of kinase inhibitor selectivity. Nat Biotechnol. 2008;26:127-32.
30. Meyer DM, Jesson MI, Li X, et al. Anti-inflammatory activity and neutrophil reductions mediated by the JAK1/JAK3 inhibitor, CP-690,550, in rat adjuvant-induced arthritis. J Inflamm (Lond). 2010;7:41.
31. Ghoreschi K, Jesson MI, Li X, Lee JL, Ghosh S, Alsup JW, et al. Modulation of innate and adaptive immune responses by tofacitinib (CP-690,550). J Immunol. 2011;186(7):4234-43. doi: 10.4049/jimmunol.1003668
32. Hodge JA, Kawabata TT, Krishnaswami S, Clark JD, Telliez JB, Dowty ME, Menon S, Lamba M, Zwillich S. The mechanism of action of tofacitinib – an oral Janus kinase inhibitor for the treatment of rheumatoid arthritis. Clin Exp Rheumatol. 2016 Mar-Apr;34(2):318.
33. De Vries LCS, Wildenberg ME, De Jonge WJ, D’Haens GR. The Future of Janus Kinase Inhibitors in Inflammatory Bowel Disease. J Crohns Colitis. 2017 Jul 1;11(7):885-93. doi: 10.1093/ecco-jcc/jjx003
34. Guan Q, Zhang J. Recent Advances: The Imbalance of Cytokines in the Pathogenesis of Inflammatory Bowel Disease. Mediat Inflam. 2017;2017:4810258. doi: 10.1155/2017/4810258
35. Heller F, Florian P, Bojarski C, et al. Interleukin-13 is the key effector Th2 cytokine in ulcerative colitis that affects epithelial tight junctions, apoptosis, and cell restitution. Gastroenterology. 2005;129:550-64.
36. Ueno A, Ghosh A, Hung D, Li J, Jijon H. Th17 plasticity and its changes associated with inflammatory bowel disease. World J Gastroenterol. 2015 Nov 21;21(43):12283-95. doi: 10.3748/wjg.v21.i43.122
37. Huber S, Gagliani N, Flavell RA. Life, death, and miracles: Th17 cells in the intestine. Eur J Immunol. 2012;42:2238-45. doi: 10.1002/eji.201242619
38. Hueber W, Sands BE, Lewitzky S, Secukinumab in Crohn’s Disease Study Group, et al. Secukinumab, a human anti-IL-17A monoclonal antibody, for moderate to severe Crohn’s disease: unexpected results of a randomised, double-blind placebo-controlled trial. Gut. 2012;61:1693-700.
39. Danese S, Vermeire S, Hellstern P, Panaccione R, Rogler G, Fraser G, Kohn A, Desreumaux P, Leong RW, Comer GM, Cataldi F, Banerjee A, Maguire MK, Li C, Rath N, Beebe J, Schreiber S. Randomised trial and open-label extension study of an anti-interleukin-6 antibody in Crohn’s disease (ANDANTE I and II). Gut. 2017 Dec 15. pii: gutjnl-2017-314562. doi: 10.1136/gutjnl-2017-314562
40. Fernández-Clotet A, Castro-Poceiro J, Panés J. Tofacitinib for the treatment of ulcerative colitis. Expert Rev Clin Immunol. 2018 Nov;14(11):881-92. doi: 10.1080/1744666X.2018.1532291
41. Izzo R, Bevivino G, Monteleone G. Tofacitinib for the treatment of ulcerative colitis. Expert Opin Investig Drugs. 2016;25:991-7.
42. Sandborn WJ, Ghosh S, Panes J, et al. Tofacitinib, an oral Janus kinase inhibitor, in active ulcerative colitis. N Engl J Med. 2012;367:616-24.
43. Sandborn WJ, Su C, Sands BE, et al. OCTAVE Induction 1, OCTAVE Induction 2, and OCTAVE Sustain Investigators. Tofacitinib as induction and maintenance therapy for ulcerative colitis. N Engl J Med. 2017;376:1723-36.
44. Panés J, Vermeire S, Lindsay JO, Sands BE, Su C, et al. Tofacitinib in Patients with Ulcerative Colitis: Health-Related Quality of Life in Phase 3 Randomised Controlled Induction and Maintenance Studies. J Crohns Colitis. 2018 Nov 8. doi: 10.1093/ecco-jcc/jjy135
45. Hanauer S, Panaccione R, Danese S, Cheifetz A, Reinisch W, et al. Tofacitinib Induction Therapy Reduces Symptoms Within 3 Days for Patients With Ulcerative Colitis. Clin Gastroenterol Hepatol. 2018 Sep 10. pii: S1542-3565(18)30709-2. doi: 10.1016/j.cgh.2018.07.009
46. Bonovas S, Lytras T, Nikolopoulos G, Peyrin-Biroulet L, Danese S. Systematic review with network meta-analysis: comparative assessment of tofacitinib and biological therapies for moderate-to-severe ulcerative colitis. Aliment Pharmacol Ther. 2018;47(4):454-65. doi: 10.1111/apt.14449
47. Sandborn WJ, Ghosh S, Panes J, Vranic I, Wang W, Niezychowski W; Study A3921043 Investigators. A phase 2 study of tofacitinib, an oral Janus kinase inhibitor, in patients with Crohn's disease. Clin Gastroenterol Hepatol. 201;12(9):1485-93.e2. doi: 10.1016/j.cgh.2014.01.029
48. Vermeire S, Schreiber S, Petryka R, Kuehbacher T, Hebuterne X, et al. Clinical remission in patients with moderate-to-severe Crohn’s disease treated with filgotinib (the FITZROY study): results from a phase 2, double-blind, randomised, placebo-controlled trial. Lancet. 2017;389(10066):266-75. doi: 10.1016/S0140-6736(16)32537
49. Flamant M, Roblin X. Inflammatory bowel disease: towards a personalized medicine. Ther Adv Gastroenterol. 2018 Jan 10;11:1756283X17745029.
________________________________________________
1. Ordás I, Eckmann L, Talamini M, Baumgart DC, Sandborn WJ. Ulcerative colitis. Lancet. 2012;380(9853):1606-19. doi: 10.1016/S0140-6736(12)60150-0
2. Baumgart DC, Sandborn WJ. Crohn's disease. Lancet. 2012;380(9853):1590-605. doi: 10.1016/S0140-6736(12)60026-9
3. Park JH, Peyrin-Biroulet L, Eisenhut M, Shin JI. IBD immunopathogenesis: A comprehensive review of inflammatory molecules. Autoimmun Rev. 2017 Apr;16(4):416-26. doi: 10.1016/j.autrev.2017.02.013
4. De Souza HS, Fiocchi C. Immunopathogenesis of IBD: current state of the art. Nat Rev Gastroenterol Hepatol. 2016;13:13-27.
5. Ahluwalia B, Moraes L, Magnusson MK, Öhman L. Immunopathogenesis of inflammatory bowel disease and mechanisms of biological therapies. Scand J Gastroenterol. 2018;53(4):379-89. doi: 10.1080/00365521.2018.1447597
6. Neurath MF. Cytokines in inflammatory bowel disease. Nat Rev Immunol. 2014;14(5):329-42.
7. Chen ML, Sundrud MS. Cytokine networks and T-cell subsets in inflammatory bowel diseases. Inflam Bow Dis. 2016;22(5):1157-67. doi: 10.1097/MIB.0000000000000714
8. Rogler G. Resolution of inflammation in inflammatory bowel disease. Lancet Gastroenterol Hepatol. 2017;2(7):521-30. doi: 10.1016/S2468-1253(17)30031-6
9. Neurath M. Current and emerging therapeutic targets for IBD. Nat Rev Gastroenterol Hepatol. 2017;14(11):688. doi: 10.1038/nrgastro.2017.138
10. Kalliolias GD, Ivashkiv LB. TNF biology, pathogenetic mechanisms and emerging therapeutic strategies. Nat Rev Rheumatol. 2016;12:49-62.
11. Levin AD, Wildenberg ME, van den Brink GR. Mechanism of Action of Anti-TNF Therapy in Inflammatory Bowel Disease. J Crohns Colitis. 2016 Aug;10(8):989-97. doi: 10.1093/ecco-jcc/jjw053. Epub 2016 Feb 19.
12. Berns M, Hommes DW. Anti-TNF-alpha therapies for the treatment of Crohn’s disease: the past, present and future. Expert Opin Investigat Drug. 2016;25(2):129-43. doi: 10.1517/13543784.2016.1126247
13. Dart RJ, Samaan MA, Powell N, Irving PM. Vedolizumab: toward a personalized therapy paradigm for people with ulcerative colitis. Clin Exp Gastroenterol. 2017;10:57-66.
14. Amiot A, Grimaud JC, Peyrin-Biroulet L, et al. Effectiveness and safety of vedolizumab induction therapy for patients with inflammatory bowel disease. Clin Gastroenterol Hepatol. 2016;14(11):1593-601. doi: 10.1016/j.cgh.2016.02.016. e2
15. Vermeire S, Gils A, Accossato P, Lula S, Marren A. Immunogenicity of biologics in inflammatory bowel disease. Ther Adv Gastroenterol. 2018 Jan 21;11:1756283X17750355. doi: 10.1177/1756283X177
16. Schwartz DM, Kanno Y, Villarino A, Ward M, Gadina M, O’Shea JJ. JAK inhibition as a therapeutic strategy for immune and inflammatory diseases. Nat Rev Drug Discov. 2017 Dec;16(12):843-62. doi: 10.1038/nrd.2017.201. Epub 2017 Nov 6.
17. Winthrop KL. The emerging safety profile of JAK inhibitors in rheumatic disease. Nat Rev Rheumatol. 2017 Apr;13(4):234-43. doi: 10.1038/nrrheum.2017.23
18. Banerjee S, Biehl A, Gadina M, Hasni S, Schwartz DM. JAK-STAT Signaling as a Target for Inflammatory and Autoimmune Diseases: Current and Future Prospects. Drugs. 2017 Apr;77(5):521-46. doi: 10.1007/s40265-017-0701-9
19. Насонов Е.Л. Новые подходы к фармакотерапии ревматоидного артрита: тофацитиниб. Научно-практическая ревматология. 2014;52(2):209-21 [Nasonov EL. New approaches to pharmacotherapy of rheumatoid arthritis: tofacitinib. Nauchno-Prakticheskaya Revmatologiya = Rheumatology Science and Practice. 2014;52(2):209-21 (In Russ.)]. doi: 10.14412/1995-4484-2014-209-221
20. Baker KF, Isaacs JD. Novel therapies for immune-mediated inflammatory diseases: What can we learn from their use in rheumatoid arthritis, spondyloarthritis, systemic lupus erythematosus, psoriasis, Crohn's disease and ulcerative colitis? Ann Rheum Dis. 2018 Feb;77(2):175-87. doi: 10.1136/annrheumdis-2017-211555
21. Panés J, Sandborn WJ, Schreiber S, Sands BE, Vermeire S, et al. Tofacitinib for induction and maintenance therapy of Crohn’s disease: results of two phase IIb randomised placebo-controlled trials. Gut. 2017;66(6):1049-59. doi: 10.1136/gutjnl-2016-312735
22. Boland BS, Vermeire S. Janus Kinase Antagonists and Other Novel Small Molecules for the Treatment of Crohn’s Disease. Gastroenterol Clin North Am. 2017 Sep;46(3):627-44. doi: 10.1016/j.gtc.2017.05.015
23. Soendergaard C, Bergenheim FH, Bjerrum JT, Nielsen OH. Targeting JAK-STAT signal transduction in IBD. Pharmacol Ther. 2018 Jul 23. pii: S0163-7258(18)30122-0. doi: 10.1016/j.pharmthera.2018.07.003
24. Olivera P, Danese S, Peyrin-Biroulet L. JAK inhibition in inflammatory bowel disease. Expert Rev Clin Immunol. 2017 Jul;13(7):693-703. doi: 10.1080/1744666X.2017.1291342
25. Shapina MV, Khalif IL. Efficacy and safety of tofacitinib in ulcerative colitis (literature review). Koloproktologiya. 2018;65(3):94-102 (In Russ.)
26. Hammarén HM, Virtanen AT, Raivola J, Silvennoinen O. The regulation of JAKs in cytokine signaling and its breakdown in disease. Cytokine. 2018 Apr 20. pii: S1043-4666(18)30127-3. doi: 10.1016/j.cyto.2018.03.041
27. Changelian PS, Flanaan ME, Ball DJ, et al. Prevention оf organ allograft rejection by a specific Janus kinase 3 inhibitor. Science. 2003;302:875-8.
28. Flanagan ME, Blumenkopf TA, Brisette WH, et al. Discovery of CP-690550: a potent and selective Janus kinase (JAK) inhibitor for the treatment of autoimmune diseases and organ transplantant rejection. J Med Chem. 2010;53:8468-84.
29. Karaman MW, Herrgard S, Treiber DK, et al. A quantitative analysis of kinase inhibitor selectivity. Nat Biotechnol. 2008;26:127-32.
30. Meyer DM, Jesson MI, Li X, et al. Anti-inflammatory activity and neutrophil reductions mediated by the JAK1/JAK3 inhibitor, CP-690,550, in rat adjuvant-induced arthritis. J Inflamm (Lond). 2010;7:41.
31. Ghoreschi K, Jesson MI, Li X, Lee JL, Ghosh S, Alsup JW, et al. Modulation of innate and adaptive immune responses by tofacitinib (CP-690,550). J Immunol. 2011;186(7):4234-43. doi: 10.4049/jimmunol.1003668
32. Hodge JA, Kawabata TT, Krishnaswami S, Clark JD, Telliez JB, Dowty ME, Menon S, Lamba M, Zwillich S. The mechanism of action of tofacitinib – an oral Janus kinase inhibitor for the treatment of rheumatoid arthritis. Clin Exp Rheumatol. 2016 Mar-Apr;34(2):318.
33. De Vries LCS, Wildenberg ME, De Jonge WJ, D’Haens GR. The Future of Janus Kinase Inhibitors in Inflammatory Bowel Disease. J Crohns Colitis. 2017 Jul 1;11(7):885-93. doi: 10.1093/ecco-jcc/jjx003
34. Guan Q, Zhang J. Recent Advances: The Imbalance of Cytokines in the Pathogenesis of Inflammatory Bowel Disease. Mediat Inflam. 2017;2017:4810258. doi: 10.1155/2017/4810258
35. Heller F, Florian P, Bojarski C, et al. Interleukin-13 is the key effector Th2 cytokine in ulcerative colitis that affects epithelial tight junctions, apoptosis, and cell restitution. Gastroenterology. 2005;129:550-64.
36. Ueno A, Ghosh A, Hung D, Li J, Jijon H. Th17 plasticity and its changes associated with inflammatory bowel disease. World J Gastroenterol. 2015 Nov 21;21(43):12283-95. doi: 10.3748/wjg.v21.i43.122
37. Huber S, Gagliani N, Flavell RA. Life, death, and miracles: Th17 cells in the intestine. Eur J Immunol. 2012;42:2238-45. doi: 10.1002/eji.201242619
38. Hueber W, Sands BE, Lewitzky S, Secukinumab in Crohn’s Disease Study Group, et al. Secukinumab, a human anti-IL-17A monoclonal antibody, for moderate to severe Crohn’s disease: unexpected results of a randomised, double-blind placebo-controlled trial. Gut. 2012;61:1693-700.
39. Danese S, Vermeire S, Hellstern P, Panaccione R, Rogler G, Fraser G, Kohn A, Desreumaux P, Leong RW, Comer GM, Cataldi F, Banerjee A, Maguire MK, Li C, Rath N, Beebe J, Schreiber S. Randomised trial and open-label extension study of an anti-interleukin-6 antibody in Crohn’s disease (ANDANTE I and II). Gut. 2017 Dec 15. pii: gutjnl-2017-314562. doi: 10.1136/gutjnl-2017-314562
40. Fernández-Clotet A, Castro-Poceiro J, Panés J. Tofacitinib for the treatment of ulcerative colitis. Expert Rev Clin Immunol. 2018 Nov;14(11):881-92. doi: 10.1080/1744666X.2018.1532291
41. Izzo R, Bevivino G, Monteleone G. Tofacitinib for the treatment of ulcerative colitis. Expert Opin Investig Drugs. 2016;25:991-7.
42. Sandborn WJ, Ghosh S, Panes J, et al. Tofacitinib, an oral Janus kinase inhibitor, in active ulcerative colitis. N Engl J Med. 2012;367:616-24.
43. Sandborn WJ, Su C, Sands BE, et al. OCTAVE Induction 1, OCTAVE Induction 2, and OCTAVE Sustain Investigators. Tofacitinib as induction and maintenance therapy for ulcerative colitis. N Engl J Med. 2017;376:1723-36.
44. Panés J, Vermeire S, Lindsay JO, Sands BE, Su C, et al. Tofacitinib in Patients with Ulcerative Colitis: Health-Related Quality of Life in Phase 3 Randomised Controlled Induction and Maintenance Studies. J Crohns Colitis. 2018 Nov 8. doi: 10.1093/ecco-jcc/jjy135
45. Hanauer S, Panaccione R, Danese S, Cheifetz A, Reinisch W, et al. Tofacitinib Induction Therapy Reduces Symptoms Within 3 Days for Patients With Ulcerative Colitis. Clin Gastroenterol Hepatol. 2018 Sep 10. pii: S1542-3565(18)30709-2. doi: 10.1016/j.cgh.2018.07.009
46. Bonovas S, Lytras T, Nikolopoulos G, Peyrin-Biroulet L, Danese S. Systematic review with network meta-analysis: comparative assessment of tofacitinib and biological therapies for moderate-to-severe ulcerative colitis. Aliment Pharmacol Ther. 2018;47(4):454-65. doi: 10.1111/apt.14449
47. Sandborn WJ, Ghosh S, Panes J, Vranic I, Wang W, Niezychowski W; Study A3921043 Investigators. A phase 2 study of tofacitinib, an oral Janus kinase inhibitor, in patients with Crohn's disease. Clin Gastroenterol Hepatol. 201;12(9):1485-93.e2. doi: 10.1016/j.cgh.2014.01.029
48. Vermeire S, Schreiber S, Petryka R, Kuehbacher T, Hebuterne X, et al. Clinical remission in patients with moderate-to-severe Crohn’s disease treated with filgotinib (the FITZROY study): results from a phase 2, double-blind, randomised, placebo-controlled trial. Lancet. 2017;389(10066):266-75. doi: 10.1016/S0140-6736(16)32537
49. Flamant M, Roblin X. Inflammatory bowel disease: towards a personalized medicine. Ther Adv Gastroenterol. 2018 Jan 10;11:1756283X17745029.
1 ФГБНУ «Научно-исследовательский институт ревматологии им. В.А. Насоновой», Москва, Россия;
2 ФГАОУ ВО «Первый Московский государственный медицинский университет им. И.М. Сеченова» Минздрава России (Сеченовский Университет), кафедра ревматологии Института профессионального образования, Москва, Россия;
3 ФГБОУ ВО «Казанский государственный медицинский университет» Минздрава России, Казань, Россия
________________________________________________
E.L. Nasonov1,2, D.I. Abdulganieva3, I.F. Fairushina3
1 V.A. Nasonova Research Institute of Rheumatology, Moscow, Russia;
2 I.M. Sechenov First Moscow State Medical University of the Ministry of Health of the Russian Federation (Sechenov University), Moscow, Russia;
3 Kazan State Medical University of the Ministry of Health of the Russian Federation, Kazan, Russia